ASK REDCHAT ANYTHING ABOUT INTENSITY THERAPEUTICS INC.
Intensity Therapeutics Inc. (NASDAQ: INTS)
Listen to this Section
$4.04
-0.0400
(
-0.98% )
0.1K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| INT230-6DetailsSarcoma |
Phase 3 |
| INT230-6DetailsBreast cancer |
Phase 2 |
| INT230-6 w/ KeytrudaDetailsPancreatic cancer, Colorectal cancer |
Phase 2 |
| INT230-6 w/ YervoyDetailsLiver cancer, Sarcoma, Breast cancer |
Phase 2 |
Market Data
| Open |
$4.04 |
| Previous Close |
$4.08 |
| Volume |
0.1K |
| Market Cap |
$11.03M |
| Day Range |
$4.03 - $4.03 |
| 52 Week Range |
$3.51 - $43.50 |
| Shares Outstanding |
2.70M |
| Change % |
-0.98% |
| Net Change |
▼ -0.0400 |
| Insider Ownership |
-0.05% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2023 |
| Country | United States |
| Underwriter | The Benchmark Company, Freedom Capital Markets, more |
Insider Ownership Transactions
Total Amount Purchased:
-770,805.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-06-07 |
Sale |
-1000.00 |
Wesolowski John M |
| 2024-05-15 |
Sale |
-50000.00 |
DUBIN THOMAS I H |
| 2024-03-07 |
Sale |
-464805.00 |
BENDER LEWIS H |
| 2024-03-07 |
Sale |
-50000.00 |
Donovan Daniel |
| 2024-03-07 |
Sale |
-50000.00 |
GOLDBERG MARK A |
| 2024-03-07 |
Sale |
-50000.00 |
Leahy Emer |
| 2024-03-07 |
Sale |
-25000.00 |
Wesolowski John M |
| 2023-12-12 |
Sale |
-80000.00 |
Talamo Joseph |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| 10-q |
Quarterly Reports |
67 |
Nov 06, 2025 |
| 8-k |
8K-related |
14 |
Nov 06, 2025 |
| 8-k |
8K-related |
18 |
Oct 31, 2025 |
| 8-k |
8K-related |
12 |
Oct 23, 2025 |
| 8-k |
8K-related |
12 |
Sep 10, 2025 |
| def |
Proxies and info statements |
13 |
Sep 09, 2025 |
| pre |
Proxies and info statements |
13 |
Aug 28, 2025 |
| 8-k |
8K-related |
13 |
Aug 12, 2025 |
| 10-q |
Quarterly Reports |
67 |
Aug 07, 2025 |
| 8-k |
8K-related |
14 |
Aug 07, 2025 |